With the optimization and adjustment of pandemic prevention policies, pandemic prevention and control measures across the country are gradually being relaxed. The number of people in home quarantine and the number of patients visiting fever clinics have increased significantly in various regions. The situation of pandemic prevention and control is severe and complex, and the demand for pandemic prevention and control drugs and supplies has dramatically increased. The market demand for "Human Immunoglobulin (pH4) for Intravenous Injection" produced by Yuanda Shuyang Pharmaceutical has also been growing. In order to ensure pandemic prevention and control and meet the clinical medication needs, the company has planned, organized, arranged, and taken action early to ensure the production and supply of pandemic prevention and emergency drugs such as " Human Immunoglobulin (pH4) for Intravenous Injection".

The company adheres to the principle of "doing both pandemic prevention and production, without neglecting either". To reduce employee contact and break the chain of virus transmission, the company's pandemic prevention and control leadership team has decisively decided to comprehensively upgrade pandemic prevention and control requirements. They have organized closed-loop production and followed the Enterprise Pandemic Prevention and Control Emergency Plan to reserve materials and centrally purchase pandemic prevention supplies. This ensures the normal life and orderly work of employees in the closed-loop. From November 2022 until now, the company has been maintaining full production capacity without being affected by the pandemic.

The company promptly pays attention to market changes, analyzes and predicts the changes in the pandemic and the demand for clinical medication after adjustments in pandemic control policies, and adjusts product production and supply plans in a timely manner to maximize meeting market demand. At the same time, the company collaborates with partners in various regions to overcome the severe impact of the pandemic and ensure that products such as "Human Immunoglobulin (pH4) for Intravenous Injection" are sent to hospitals nationwide as soon as possible.

"Human Immunoglobulin (pH4) for Intravenous Injection" is an immunoglobulin mixture separated and extracted from the plasma of healthy blood donors. It contains approximately 107 broad-spectrum antibodies against viruses, bacteria, and other exogenous antigens, as well as antibodies against self-antigens. It can exert extensive immunomodulatory and anti-inflammatory effects.

Recently, the Health Commission of Guangdong Province issued a notice titled Notice from the Office of the Health Commission of Guangdong Province on Ensuring the Supply of Drugs for COVID-19 and Clinical Pharmacy Services. The "Human Immunoglobulin (pH4) for Intravenous Injection" has been included in the recommended drug reserve list for the treatment of COVID-19, emergency treatment, and chronic diseases.

Yuanda Shuyang Pharmaceutical has always adhered to the business philosophy of benevolence and integrity, and has demonstrated responsibility and commitment through dedication and perseverance. The company strives to fulfill its social responsibilities and makes every effort to meet the medication needs of the public.